致幻剂的潜在治疗效应:机制与分子靶点
致幻剂(经典致幻剂)在神经精神疾病和物质使用障碍治疗中显示出潜力,临床试验提示其可缓解抑郁和焦虑症状,并促进尼古丁和酒精使用量显著下降。其持续治疗效应的分子机制尚不明确,文献在5-HT2A受体依赖与非依赖信号通路间存在分歧,需临床与临床前研究交叉验证。
要点
- 临床试验显示致幻剂可缓解抑郁焦虑症状并减少尼古丁和酒精使用。
- 持续治疗效应的分子机制不明,5-HT2A受体依赖与非依赖通路存在争议。
- 致幻剂辅助治疗中的主观体验重要性增加,但需临床与临床前交叉验证。
核心结论
- 临床试验结果提示致幻剂有望缓解抑郁和焦虑症状,并促进尼古丁和酒精使用量显著下降。
- 致幻剂持续治疗效应的分子机制仍不清楚,5-HT2A受体依赖与非依赖信号通路均有文献支持。
- 致幻剂诱导的主观体验在治疗中的重要性日益受到关注,但缺乏临床与临床前研究的交叉验证可能影响其转化效度。
研究设计与样本
- 本文为综述,总结临床试验和临床前研究关于经典致幻剂潜在治疗效应机制与分子靶点的证据。
主要发现
- 临床试验显示致幻剂可缓解抑郁和焦虑症状,并促进尼古丁和酒精使用量显著下降。
- 临床前研究正在评估经典致幻剂急性后效应的靶点和神经环路。
- 当前文献在5-HT2A受体依赖与非依赖信号通路之间存在分歧。
- 分子、行为和遗传技术的结合开始为阐明这些机制提供希望。
- 越来越多的证据指向致幻剂辅助治疗中主观体验的重要性。
临床怎么用
- 致幻剂辅助治疗需关注主观体验,但临床决策应基于尚不明确的机制证据谨慎推进。
局限性
- 致幻剂持续治疗效应的分子原因仍知之甚少。
- 临床与临床前研究缺乏交叉验证,可能影响转化效度。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psychedelics, also known as classical hallucinogens, have been investigated for decades due to their potential therapeutic effects in the treatment of neuropsychiatric and substance use disorders. The results from clinical trials have shown promise for the use of psychedelics to alleviate symptoms of depression and anxiety, as well as to promote substantial decreases in the use of nicotine and alcohol. While these studies provide compelling evidence for the powerful subjective experience and prolonged therapeutic adaptations, the underlying molecular reasons for these robust and clinically meaningful improvements are still poorly understood. Preclinical studies assessing the targets and circuitry of the post-acute effects of classical psychedelics are ongoing. Current literature is split between a serotonin 5-HT2A receptor (5-HT2AR)-dependent or -independent signaling pathway, as researchers are attempting to harness the mechanisms behind the sustained post-acute therapeutically relevant effects. A combination of molecular, behavioral, and genetic techniques in neuropharmacology has begun to show promise for elucidating these mechanisms. As the field progresses, increasing evidence points towards the importance of the subjective experience induced by psychedelic-assisted therapy, but without further cross validation between clinical and preclinical research, the why behind the experience and its translational validity may be lost.
引用
- Jaster AM, González-Maeso J. Mechanisms and molecular targets surrounding the potential therapeutic effects of psychedelics. Mol Psychiatry. 2023. PMID: 37759040. doi:10.1038/s41380-023-02274-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。